Asia Vets Holdings Valuation

Is 5RE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 5RE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 5RE's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 5RE's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 5RE?

Key metric: As 5RE is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 5RE. This is calculated by dividing 5RE's market cap by their current revenue.
What is 5RE's PS Ratio?
PS Ratio	1.6x
Sales	S$2.56m
Market Cap	S$4.09m

5RE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 5RE's PS Ratio compare to its peers?

The above table shows the PS ratio for 5RE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	1.2x
EHG Econ Healthcare (Asia)	1x	n/a	S$58.5m
UUK Pasture Holdings	0.3x	n/a	S$6.5m
1H3 Clearbridge Health	0.2x	n/a	S$1.9m
40T ISEC Healthcare	3.2x	n/a	S$227.2m
5RE Asia Vets Holdings	1.6x	n/a	S$4.1m

Price-To-Sales vs Peers: 5RE is expensive based on its Price-To-Sales Ratio (1.6x) compared to the peer average (1.2x).

Price to Sales Ratio vs Industry

How does 5RE's PS Ratio compare vs other companies in the SG Healthcare Industry?

1 Company	Price / Sales	Estimated Growth	Market Cap
1H3 Clearbridge Health	0.2x	n/a	US$1.38m

No more companies available in this PS range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 5RE is expensive based on its Price-To-Sales Ratio (1.6x) compared to the SG Healthcare industry average (1.5x).

Price to Sales Ratio vs Fair Ratio

What is 5RE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

5RE PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	1.6x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 5RE's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

IHH Healthcare Berhad

RM 63.4b

An investment holding company, provides healthcare services in Malaysia, Singapore, Turkey, India, China, Japan, Turkey, Europe, and internationally.

Q0F

RM 2.15

-1.4%

29.5%

Yunnan Energy International

HK$209.3m

An investment holding company, distributes analytical and laboratory instruments, and life science equipment in the People’s Republic of China, Hong Kong, Macau, Oceania, Asia, and internationally.

T43

HK$0.075

n/a

Econ Healthcare (Asia)

S$58.5m

An investment holding company, engages in the operation of medicare centers and nursing homes for eldercare in Singapore, Malaysia, and China.

EHG

S$0.22

4.8%

10.0%